Strs Ohio Sells 4,401 Shares of Hologic, Inc. (NASDAQ:HOLX)

Strs Ohio lessened its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 14.2% in the fourth quarter, HoldingsChannel reports. The fund owned 26,641 shares of the medical equipment provider’s stock after selling 4,401 shares during the period. Strs Ohio’s holdings in Hologic were worth $1,903,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Macquarie Group Ltd. increased its position in Hologic by 227.2% during the second quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock worth $435,485,000 after acquiring an additional 4,363,687 shares during the period. Norges Bank acquired a new position in shares of Hologic during the 4th quarter worth approximately $175,900,000. Arrowstreet Capital Limited Partnership increased its holdings in shares of Hologic by 110.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,896,174 shares of the medical equipment provider’s stock worth $145,664,000 after purchasing an additional 995,854 shares during the period. Qube Research & Technologies Ltd raised its position in shares of Hologic by 117.2% in the third quarter. Qube Research & Technologies Ltd now owns 1,378,258 shares of the medical equipment provider’s stock valued at $95,651,000 after buying an additional 743,557 shares in the last quarter. Finally, Prudential Financial Inc. boosted its stake in shares of Hologic by 246.0% in the first quarter. Prudential Financial Inc. now owns 920,718 shares of the medical equipment provider’s stock valued at $70,730,000 after buying an additional 654,628 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Up 0.4 %

HOLX opened at $75.38 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $87.88. The company’s 50 day moving average price is $75.75 and its two-hundred day moving average price is $72.57. The firm has a market capitalization of $17.69 billion, a price-to-earnings ratio of 35.73, a PEG ratio of 2.54 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. Hologic’s revenue was down 5.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.07 earnings per share. As a group, research analysts predict that Hologic, Inc. will post 4.01 earnings per share for the current year.

Insider Buying and Selling at Hologic

In related news, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares in the company, valued at approximately $3,670,130.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the transaction, the director now owns 1,572 shares in the company, valued at approximately $119,802.12. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,846 shares of company stock worth $2,473,443. Insiders own 1.75% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on HOLX shares. UBS Group lifted their price objective on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. StockNews.com downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Evercore ISI increased their price objective on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Wednesday, April 10th. Finally, Raymond James upped their price target on shares of Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $87.00.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.